Amgen swoops in with $13.4B deal to pluck blockbuster Otezla from Celgene
Now that their Enbrel franchise appears to be secure from copycat interlopers, Amgen is going for a sure thing on the deal side to bolster its revenue projections.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
